Wed Sep 18 03:19:02 UTC 2024: ## Neuralink’s Vision-Restoring BCI Receives FDA Breakthrough Designation
Elon Musk’s Neuralink has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA) for its experimental brain-computer interface (BCI) implant, Blindsight. This designation signifies the device’s potential to revolutionize treatment for blindness by restoring vision to those who have lost both eyes and their optic nerve.
According to Musk, the device will enable even individuals born blind to see for the first time, provided their visual cortex remains intact. Though initial vision will be low resolution, akin to Atari graphics, the technology holds the potential to surpass natural vision in the future. Musk envisions the ability to see in infrared, ultraviolet, or even radar wavelengths, much like the character Geordi La Forge from Star Trek.
The FDA’s Breakthrough Device Designation is designed to accelerate the development and review process for medical devices that address life-threatening or debilitating conditions. This designation signifies a significant step forward for Neuralink’s Blindsight, and raises hopes for a future where blindness is no longer a permanent barrier to experiencing the world.
First Piper 